

## **Systematic Review and Meta-Analysis of Endovascular Therapy Effectiveness for Unruptured Saccular Intracranial Aneurysms**

Sergio A. Pineda-Castillo<sup>1</sup>, Evan R. Jones<sup>1</sup>, Keely A. Laurence<sup>1</sup>, Lauren R. Thoendel<sup>1</sup>,  
Tanner L. Cabaniss<sup>1</sup>, Yan D. Zhao<sup>2</sup>, Bradley N. Bohnstedt<sup>3</sup>, and Chung-Hao Lee<sup>1,4\*</sup>

<sup>1</sup>Biomechanics and Biomaterials Design Laboratory,  
School of Aerospace and Mechanical Engineering, The University of Oklahoma, Norman, OK,  
USA

<sup>2</sup>Department of Biostatistics and Epidemiology, The University of Oklahoma Health Sciences  
Center, Oklahoma City, OK, USA

<sup>3</sup>Department of Neurological Surgery, Indiana University School of Medicine, Indianapolis, IN,  
USA

<sup>4</sup>Department of Bioengineering, University of California Riverside, Riverside, CA, USA

\* Corresponding Author

Contact Information (author name, e-mail, phone number, full mailing address):

C.-H. Lee, [ch.lee@ou.edu](mailto:ch.lee@ou.edu), +1 (405)325-4842, 865 Asp Ave. Felgar Hall 219C, 865 Asp Ave.,  
Norman, OK 73019, USA

## 1 ABSTRACT

2 Background: Currently, endovascular treatment of intracranial aneurysms (ICAs) is limited by  
3 low complete occlusion rates. The advent of novel endovascular technology has expanded the  
4 applicability of endovascular therapy; however, the superiority of novel embolic devices over  
5 the traditional Guglielmi detachable coils (GDCs) is still debated. We performed a systematic  
6 review of literature that reported the Raymond-Roy occlusion classifications (RROC) rates of  
7 modern endovascular devices to determine their immediate and long-term occlusion  
8 effectiveness for the treatment of unruptured saccular ICAs.

9 Methods: A search was conducted using electronic databases (PUBMED, Cochrane,  
10 ClinicalTrials.gov, Web of Science). We retrieved studies published between 2000-2022  
11 reporting immediate and long-term RROC rates of subjects treated with different endovascular  
12 ICA therapies. We extracted demographic information of the treated patients and their reported  
13 angiographic RROC rates.

14 Results: A total of 80 studies from 15 countries were included for data extraction. RROC rates  
15 determined from angiogram were obtained for 21,331 patients (72.5% females, pooled mean  
16 age: 58.2 (95% CI: 56.8-59.6), harboring 22,791 aneurysms. The most frequent aneurysm  
17 locations were the internal carotid artery (46.4%, 95% CI: 41.9%-50.9%), the anterior  
18 communicating artery (26.4%, 95% CI: 22.5%-30.8%), the middle cerebral artery (24.5%,  
19 95% CI:19.2%-30.8%) and the basilar tip (14.4%, 95% CI:11.3%-18.3%). The RROC rates  
20 were analyzed for GDCs, the Woven EndoBridge (WEB), and flow diverters. The immediate  
21 complete occlusion (RROC-I) rate was the highest in balloon-assisted coiling (73.9%, 95% CI:  
22 65.0%-81.2%) and the lowest in the WEB (27.8%, 95% CI:13.2%-49.2%). The long-term  
23 complete occlusion probability was homogenous in all analyzed devices.

24 Conclusions: We observed that the coil-based endovascular therapy provides acceptable rates  
25 of complete occlusion, where the balloon-assisted coils provide greater probability of  
26 immediate complete occlusion. Out of the analyzed devices, the WEB exhibited the shortest  
27 time to achieve >90% probability of long-term complete occlusion (~18 months). Overall, the  
28 GDCs remain the *gold standard* for endovascular treatment of unruptured saccular aneurysms.

29  
30 **KEYWORDS:** endovascular therapy, intracranial aneurysms, flow diverters, Woven  
31 EndoBridge, Guglielmi detachable coils

## 32 INTRODUCTION

33 Endovascular treatment of intracranial aneurysms (ICA) emerged in 1991 with the invention of  
34 the Guglielmi detachable coils (GDCs).<sup>1,2</sup> Ever since, endovascular treatment has become the  
35 preferred method for ICA therapy due to its minimal invasiveness, lower in-hospital fatalities,  
36 and superior clinical outcomes, when compared to the traditional, highly invasive surgical  
37 clipping.<sup>3-6</sup> In addition, the coupling of GDCs and other assisting technology, such as balloons  
38 and stents, has increased their range of applications and effectiveness, especially for  
39 aneurysm with a complex 3D geometry or a high neck-to-sack ratio.<sup>7</sup>

40 In the last two decades, novel endovascular devices have been designed to expand the  
41 application of this minimally invasive method for ICA therapy. The most prominent inventions  
42 include bioactive and hydrogel-coated GDCs and flow diverters.<sup>7,8</sup> For flow diverters,  
43 numerous devices have emerged in two categories: (i) extra-saccular: including the p64,<sup>9</sup> the  
44 Pipeline,<sup>10</sup> the Flow Redirection Endoluminal Device (FRED),<sup>11</sup> the Surpass,<sup>12</sup> among others;  
45 and (ii) intra-saccular flow diverters: such as the Woven EndoBridge (WEB)<sup>13</sup> and the  
46 Contour.<sup>14</sup> The advance of this technology has evolved the application of endovascular therapy  
47 for complex aneurysm geometries and even aneurysm locations within the neuro-vasculature.

48 Despite these advancements, current literature has shown that the modern endovascular  
49 devices do not demonstrate superior complete occlusion rates than the traditional GDCs for  
50 the treatment of unruptured ICAs.<sup>15</sup> Considering that incomplete occlusion drives the  
51 recurrence of the treated aneurysm,<sup>16</sup> it is of paramount importance that advances in  
52 endovascular therapy are aimed at improving the limited complete occlusion rates of the  
53 GDCs. However, meta-analyses aimed to compare the occlusion effectiveness of different  
54 endovascular devices are limited by a low sample size (i.e., low number of analyzed studies)  
55 and the use of few timepoints for the comparison of long-term occlusion effectiveness. Owing  
56 to the great success of novel technologies for endovascular therapy, in this study our objective  
57 is to perform a comprehensive assessment of the complete occlusion effectiveness of modern  
58 endovascular devices to re-evaluate the notion of the GDCs as the *gold standard* in  
59 endovascular therapy of unruptured saccular ICAs. In addition, we also present a long-term  
60 occlusion effectiveness analysis of modern endovascular devices.

## 61 METHODS

### 62 Literature Search

63 A systematic literature search was conducted by following the recommendations of Tawfik *et*  
64 *al.*,<sup>17</sup> the Preferred Reporting Items for the Systematic Reviews and Meta-Analyses (PRISMA)  
65 statement,<sup>18</sup> and the Cochrane Handbook for Systematic Reviews of Interventions.<sup>19</sup> Briefly, a  
66 search was performed using online databases available at our institution: PubMed, Cochrane,  
67 Web of Science, and ClinicalTrials.gov. The search was conducted to obtain both prospective  
68 and retrospective studies that were conducted to evaluate the occlusion efficacy of  
69 endovascular devices for treating unruptured saccular ICAs, including GDCs, hydrogel-coated  
70 coils, WEB, flow diverters, liquid embolic devices, and others. Only peer-reviewed studies  
71 published between 2000-2022, with recruitment start date on or after 1999, were included in  
72 the screening process. A complete set of queries for the database search can be found in  
73 **Supplemental Data S1.**

#### 74 *Inclusion/Exclusion of Studies*

75 Screening of the search results was performed using a list of Inclusion/Exclusion (I/E) criteria;  
76 individual studies not adhering to the I/E criteria were rejected for data collection. Some key  
77 inclusion criteria (IC) were:

- 78 1. Reporting of the occlusion rates with Raymond-Roy occlusion classification (RROC) or  
79 a translatable scale.
- 80 2. Treating unruptured saccular aneurysms only (in the case of including ruptured  
81 aneurysms in study design, occlusion rates must be reported separately per rupture  
82 status).
- 83 3. Reporting of long-term follow-up of ICA occlusion.
- 84 4. Endovascular treatment must be performed as the first line of treatment for the target  
85 ICA.

86 Exclusion criteria (EC) included:

- 87 1. Literature reviews.
- 88 2. Case studies.
- 89 3. Unrelated articles.
- 90 4. Animal studies.
- 91 5. Studies including trauma-induced, mycotic, pathogen-induced aneurysms.
- 92 6. Studies that reported occlusion rates with no discrimination of saccular and non-  
93 saccular geometries (i.e., saccular geometries should be reported separately).

94 A complete list of the I/E criteria can be found in **Supplemental Data S2**. The first stage of  
95 screening was performed by three independent reviewers using a spreadsheet containing the  
96 title and abstract of the search results after removing duplicates. Then, the second screening  
97 was performed by four reviewers by reading the full manuscript. All the studies included after  
98 screening were used for data collection.

### 99 Data Collection

100 Data collection was performed by two reviewers. Studies were distributed proportionally  
101 between reviewers, and data was extracted using a standardized spreadsheet that was  
102 previously pilot tested. Data extracted for analysis included: (i) *basic study information* (first  
103 author, country, publication date, sample size), (ii) *patient demographics* (age and sex), (iii)  
104 *aneurysm dimensions* (largest diameter and neck length), (iv) *location in the Circle of Willis*  
105 (**Table 1**), and (v) *aneurysm occlusion effectiveness results* (type of endovascular device,  
106 angiographic assessment time, follow-up time, number of aneurysms assessed, and RROC  
107 rates). After initial data collection, studies were re-distributed among the reviewers to perform  
108 another step of data verification, to confirm correct data extraction.

### 109 Outcomes

110 The objective of this meta-analysis was to compare the immediate and long-term occlusion  
111 rates of modern endovascular devices for treating unruptured ICAs. In addition, the  
112 demographic information about ICA size and location on the Circle of Willis was collected and  
113 the corresponding meta-averages and meta-proportions were analyzed.

### 114 Statistical Analysis

115 Summary statistics reported in individual studies were transformed to obtain the  
116 mean  $\pm$  standard deviation (SD) of each extracted metric. Proportions, averages, and their  
117 respective 95% confidence interval (CI) were pooled across studies using a random-effects  
118 mixed model meta-analysis. Heterogeneity was quantified using  $I^2$ . A logistic generalized  
119 linear mixed model (LGLMM) was used to compare the time-dependent complete occlusion  
120 probability between different endovascular devices. All statistical analyses were performed in  
121 R v4.1.2 using the meta-package<sup>20</sup>.


122 **Table 1.** List of aneurysm locations at the Circle of Willis and their corresponding acronyms.

<i>Circulation</i>	<i>Artery</i>	<i>Acronym</i>	<i>Portions</i>
<i>Anterior</i>	<i>Anterior Communicating Artery</i>	<i>ACommA</i>	
	<i>Anterior Cerebral Artery</i>	<i>ACA</i>	<i>A1,A2</i>
	<i>Middle Cerebral Artery</i>	<i>MCA</i>	
	<i>Internal Carotid Artery</i>	<i>ICaA</i>	
	<i>Anterior Choroidal Artery</i>	<i>AChA</i>	
	<i>Anteromedial Central Arteries</i>	<i>ACeA</i>	
<i>Posterior</i>	<i>Posterior Cerebral Artery</i>	<i>PCA</i>	<i>P1,P2</i>
	<i>Posterior Communicating Artery</i>	<i>PCommA</i>	
	<i>Posteromedial Central Arteries</i>	<i>PCeA</i>	
	<i>Superior Cerebral Artery</i>	<i>SCA</i>	
	<i>Pontine Arteries</i>	<i>PA</i>	
	<i>Basilar Artery</i>	<i>BA</i>	<i>Tip, Trunk</i>
	<i>Internal Auditory Artery</i>	<i>IAA</i>	
	<i>Anterior Spinal Artery</i>	<i>ASA</i>	
	<i>Anterior Inferior Cerebellar Artery</i>	<i>AICA</i>	
	<i>Posterior Inferior Cerebellar Artery</i>	<i>PICA</i>	
	<i>Vertebral Artery</i>	<i>VA</i>	

123 **RESULTS**

124 *Literature Search Results and Screening*

125 Literature search was performed on November 7<sup>th</sup>, 2022, and yielded 5,227 results, which  
 126 were included in the screening pipeline presented in **Figure 1**. A total of 80 studies were  
 127 included for data extraction. A complete list of the included studies is provided in  
 128 **Supplemental Data 3**.



129

130

131

**Figure 1.** Flow diagram of the screening of obtained studies. *n* represents the number of studies that were included after each phase of the screening process.

132

### Patient and Study Demographics

133

In total, the 80 studies used for data extraction included 21,331 patients from 15 countries that harbored 22,791 aneurysms. See **Supplemental Data S4** for these studies included in data extraction. The pooled female proportion was 72.5% (95% CI: 70.9%-74.2%). The pooled mean patient age was 58.2 (95% CI: 56.8-59.6, **Table 2**). The overall aneurysm maximum diameter average and neck size were 7.2 mm (95% CI: 6.5-7.8 mm) and 4.4 mm (95% CI: 4.1-4.7 mm), respectively (**Table 2**). The pooled proportions of aneurysm location are listed in **Table 3**, whereas the pooled follow-up time was 13.0 months (95% CI: 10.2-15.8 months).

140

**Table 2.** Patient demographics and meta-averages of aneurysm dimensions.

<b>Patient Demographics</b>		<b><i>n</i> = 21,331</b>
Female		72.5 (70.8-74.1)
Age		58.1 (56.7-59.5)
<b>ICA Geometry</b>		<b>Mean (95% CI)</b>
Average maximum diameter (mm)		7.1 (6.5-7.8)
Average neck width (mm)		4.3 (4.0-4.6)

141

**Table 3.** Meta-proportions of ICA anatomic location on the circle of Willis.

<b>ICA Anatomic Location</b>	<b>% (95% CI)</b>
ACommA	26.4 (22.5-30.8)
ACA – A1	10.2 (6.1-16.8)
ACA – A2	7.4 (0.6-52.4)

<i>MCA</i>	24.5 (19.2-30.8)
<i>ICaA</i>	46.4 (41.9-50.9)
<i>AChA</i>	3.4 (3.1-3.8)
<i>ACEA</i>	1.8 (1.6-2.2)
<i>PCA – P1</i>	2.7 (1.3-5.5)
<i>PCA – P2</i>	0.8 (0.2-3.1)
<i>PCommA</i>	13.9 (12.2-15.7)
<i>PCeA</i>	1.6 (0.1-19.7)
<i>SCA</i>	4.2 (2.7-6.7)
<i>BA – Tip</i>	14.4 (11.3-18.3)
<i>BA – Trunk</i>	4.7 (2.2-9.8)
<i>IAA</i>	0.7 (0.2-2.3)
<i>PICA</i>	2.9 (1.7-5.0)
<i>VA</i>	3.0 (2.0-4.5)

142 Overall, 20,874 ICAs had angiogram-determined occlusion rates reported immediately after  
 143 treatment or at the earliest follow-up (for flow-diverters only). From this subset, 15,713 (74.9%)  
 144 were treated with coiling alone, 3,206 (15.3%) with stent-assisted coiling (SAC), 782 (3.72%)  
 145 with balloon-assisted coiling (BAC), 896 (4.26%) with flow diverters, 270 (1.2%) with the  
 146 Woven-EndoBridge (WEB), and 158 (0.75%) with other endovascular technologies (i.e.,  
 147 hydrogel-coated coils, Contour Neurovascular system, and Medina).

#### 148 Occlusion Effectiveness

149 The meta-analysis of aneurysm occlusion effectiveness was performed in three parts: (i) the  
 150 pooled meta-proportion of the immediate complete IAC occlusion (i.e., RROC-I rates), (ii) the  
 151 long-term occlusion effectiveness using a LGLMM, and (iii) a comparison of the last available  
 152 follow-up complete occlusion meta-proportion and the predicted probability of complete  
 153 occlusion at the average follow-up time based on the LGLMM. All the analyses were  
 154 performed with the extracted RROC-I rates for Coils (grouped as coiling-alone and assisted-  
 155 coiling techniques), WEB device, and flow diverters. Other devices (hydrogel-coated coils,  
 156 Contour Neurovascular system) were excluded from the analysis due to a relatively low  
 157 number of studies available but are included in the overall discussion.

#### 158 Immediate Occlusion after Endovascular Treatment

159 The proportions for RROC-I rates immediately after the endovascular therapy were obtained  
 160 for each study. A proportion meta-analysis was performed to pool study proportions using a  
 161 random effects model. A meta-proportion for each individual device is shown in **Table 4**. These  
 162 proportions represent the global complete occlusion rate obtained in all the studies for each  
 163 device and its confidence interval. Flow diverters were not analyzed immediately after  
 164 treatment due to the nature of its mechanism of action, where the target aneurysms become



165 progressively occluded over time (i.e., no occlusion occurs immediately after treatment but 2-6  
166 months after the treatment).

### 167 Long-Term Occlusion Effectiveness of Endovascular Treatment

168 Binomial LGLMM models were fitted to the occlusion effectiveness data obtained from the 80  
169 studies. Three models were obtained for the probability of RROC-I for each individual device  
170 categories as a function of angiographic follow-up time: (i) all coiling techniques (i.e., bare  
171 coils, SAC, and BAC), (ii) the WEB device, and (iii) flow diverters. The models for other  
172 devices were not performed due to a relatively low number of available studies. An individual  
173 model for BAC was attempted; however, this was not possible because of the low availability  
174 of follow-up time points for this technique. Therefore, only one model for all available coiling  
175 data was performed. The corresponding model parameters are summarized in **Table 5** and the  
176 models fits are shown in **Figure 2**. In addition, the traditional fixed-effects logistic models  
177 (FELM) were compared to the LGLMM to demonstrate how the random effects were induced  
178 by individual study variation.


179 Further, the pooled meta-proportions exhibit a higher degree of immediate occlusion for BAC  
180 than the other coiling techniques, whereas the WEB exhibited poor immediate occlusion  
181 degrees immediately after treatment. On the other hand, the fitted models in **Figure 2**  
182 demonstrate similar complete occlusion behaviors across the different endovascular therapy  
183 techniques. The WEB device exhibits a unique behavior, where the initial (FU time = 0 months)  
184 occlusion degree approximates the proportion described in **Table 4**, which then increases to  
185 similar levels of complete occlusion of coiling and flow diverters. Using the discrete predicted  
186 values of the models, we observed that the predicted probability of complete occlusion at 6  
187 months for coiling, WEB, and flow diverters was 0.76 (95% CI: 0.67-0.82), 0.53 (95% CI: 0.30-  
188 0.74), and 0.78 (95% CI: 0.60-0.90). At 11-12 months, the probability increased to  
189 0.79 (95% CI: 0.69-0.86) for coils, 0.74 (0.40-0.92) for WEB, and 0.83 (0.65-0.92) for flow  
190 diverters. Finally, at the last available FU point RROC-I probability was 0.91 (95% CI: 0.60-  
191 0.99) at 40 months for coiling, 0.91 (95% CI: 0.41-0.99) at 18 months for WEB, and 0.92  
192 (95% CI: 0.37-1.00) for flow diverters. Overall, long-term RROC-I probability was  
193 homogeneous across endovascular techniques.

194 **Table 4.** Pooled meta-proportions and heterogeneity of the RROC-I for modern endovascular  
195 devices, except flow diverters.

<i>Device (k studies)</i>	<i>RROC-I Meta-Proportion % (CI 95%)</i>	<i>I<sup>2</sup> (%)</i>
<i>Coiling (29)</i>	58.1 (53.4-62.7)	95.0
<i>SAC(25)</i>	56.0 (46.0-65.5)	94.2
<i>BAC (6)</i>	73.9 (65.0-81.2)	81.8
<i>WEB (6)</i>	27.8 (13.2-49.2)	77.1

196 **Table 5.** Model parameters for the LGLMM and FELM models of probability of RROC-I as a  
 197 function of follow-up (FU) time for endovascular therapy techniques. OR: odds ratio.

<i>Device</i>	<i>Parameter</i>	<i>LGLMM</i>			<i>FELM</i>		
		<i>OR</i>	<i>CI (95%)</i>	<i>p-value</i>	<i>OR</i>	<i>CI</i>	<i>p-value</i>
<i>Coiling</i>	Intercept	2.50	1.51-4.15	<0.001	1.15	1.12-1.19	<0.001
	FU time	1.04	0.98-1.09	0.199	1.03	1.03-1.04	<0.001
<i>WEB</i>	Intercept	0.37	0.08-1.63	0.187	0.49	0.37-0.64	<0.001
	FU time	1.20	0.98-1.47	0.074	1.16	1.12-1.21	<0.001
<i>Flow Diverters</i>	Intercept	2.63	0.67-10.32	0.165	0.77	0.65-0.91	0.003
	FU time	1.05	0.92-1.19	0.452	1.09	1.07-1.10	<0.001



198 **Figure 2.** LGLMM model fits for probability of RROC-I as a function of follow-up time for the  
 199 evaluated endovascular therapy techniques. Grey shading represents CI 95%.  
 200

201 **DISCUSSION**

202 *Overall Remarks and Occlusion Effectiveness*

203 In this study, 19,751 aneurysms were treated with coil-based techniques in the 22-year span of  
 204 the included studies. However, coiling exhibited limitations in its early years related to  
 205 procedural complications, such as aneurysm/parent vessel perforation, mass effect, parent  
 206 vessel occlusion and/or coil migration.<sup>21</sup> In addition, the long-term efficacy of coiling is limited  
 207 by potential coil compaction and/or aneurysm recurrence, thus leading to the need for  
 208 retreatment of the aneurysm. These limitations led to the development of assisting techniques  
 209 for coil embolization. For example, the BAC emerged as a safe alternative for ICAs with  
 210 unfavorable sack-to-neck ratios, and the SEC for more complex geometries (giant, fusiform)  
 211 with difficult-to-treat locations, such as bifurcation ICAs. Nonetheless, the overall coiling  
 212 techniques suffer from limitations, including aneurysm recurrence, difficulty to treat aneurysms  
 213 with tortuous parent vessels, and high re-treatment rates.<sup>22</sup>

214 Based on the limitations of endovascular coil embolization, flow diverters emerged as a great  
 215 alternative for ICA treatment. Flow diverters are similar to stents in terms of fabrication

216 methods and materials (both are tubular wire meshes) but differ in porosity and flexibility. They  
217 aim to decouple blood flow between the parent vessel and the aneurysm space, allowing  
218 progressive thrombus formation within the aneurysm sac. In addition, the wired mesh acts as a  
219 scaffold for neo-endothelization, which can lead to complete parent vessel remodeling.<sup>23</sup> This  
220 approach has expanded the application of endovascular therapy to ICA geometries and  
221 locations that are not treatable with coiling techniques. Finally, endosaccular flow diverters, like  
222 the WEB, have expanded flow diverting technology to bifurcation aneurysms.

223 In this study, we aimed to understand the potential of these techniques for the treatment of  
224 saccular unruptured aneurysms, a broad ICA category that can be treated with most  
225 endovascular approaches. Due to the greater effect of the immediate complete occlusion in  
226 recurrence rates and retreatment,<sup>16,24</sup> understanding the overall RROC-I rate of the most  
227 prominent endovascular therapies is of paramount importance for improved therapeutic  
228 selection and the development of novel, individualized endovascular technologies.

229 The results of this meta-analysis from 22,193 unruptured saccular ICAs showed several key  
230 differences and similarities between endovascular devices. We found that the immediate ICA  
231 occlusion is improved in the BAC, when compared to other coiling techniques  
232 (73.8% [95% CI: 65.0%-81.1%] vs 56.7% [95% CI: 52.5%-60.8%]), as described previously in  
233 the literature. These differences contribute to the debate on the differences between coiling  
234 techniques, where occlusion rates have been found to be similar for coiling alone, SAC and  
235 BAC.<sup>25-27</sup> In addition, our results validate previous results for RROC-I rates immediately after  
236 treatment; we found that RROC-I pooled proportion was 27.7% (95% CI: 13.2%-49.2%),  
237 similar to what Asnafi *et al.* found in their meta-analysis for the same device:  
238 27.0% (95% CI: 15.0%-39.0%).<sup>28</sup>

239 In the longer-term post aneurysm embolization, our results indicated that different  
240 endovascular therapies provide similar levels of RROC-I rates. In the last available follow-up  
241 point, coiling, the WEB, and flow diverters exhibited >90% occlusion (**Figure 2**). However, the  
242 WEB device reached these levels of occlusion in a much shorter time (18 months), while the  
243 coiling techniques and flow diverters required at least 40 and 31.5 months, respectively, to  
244 achieve the same probability of RROC-I. Quantitatively, this was reflected by a greater odds  
245 ratio for the WEB in the GLMM model (**Table 5**). These findings would be useful to inform  
246 current guidelines for method selection for ICA endovascular therapy.

247 *Occlusion Efficacy of Other Devices*

248 In this study, we focused on obtaining the comprehensive information about modern  
249 endovascular devices used in studies that fulfilled our I/E criteria. However, not all the included  
250 studies could be analyzed in a meta-analysis (e.g., due to a low number of available studies).  
251 Specifically, two devices from two separate studies that fulfilled our I/E criteria were not  
252 included in this meta-analysis. The devices that were not analyzed were hydrogel-coated coils  
253 (HCCs) and the Contour Neurovascular System (CNS).

254 The CNS is an intrasaccular flow diverter with a similar mechanism of action as the WEB  
255 device. However, their geometries differ from the WEB and make the CNS a separate field of  
256 study for this analysis. The CNS is a braided wire mesh that is designed specifically for wide-  
257 necked bifurcation aneurysms. It has an “upside-down-umbrella” geometry that resembles the  
258 original geometry of a bifurcation when deployed in the aneurysm<sup>29</sup>. The included study by  
259 Biondi *et al.* (2022)<sup>14</sup> is a retrospective single-arm study where the CNS was tested in 53  
260 patients. Complete occlusion using the CNS was 16.7% immediately after treatment, 79.6% at  
261 3 months follow-up, and 51.8% at 1 year follow-up. It is not common to see a reduction in  
262 complete occlusion when data is available for the whole cohort across follow-up times, and this  
263 reduction is not explained in the study discussion. Future research for the CNS should shed  
264 more light on the behavior observed in this study. Also, the authors indicate that the patient  
265 cohort included their “learning curve” period for the CNS, which can also yield to biased  
266 results. Overall, the CNS is a promising device that requires further and prospective research  
267 to be included in systematic meta-analysis studies.

268 On the other hand, the HCCs are an advancement of coil-based technology where the coil is  
269 coated with a polymeric sheath, which absorbs water and swells to occupy gaps between coils.  
270 This technology was developed to increase packing density of traditional coils. Several trials  
271 have been performed to study the advantage of the HCCs over traditional coiling, but no  
272 significant differences have been found in immediate complete occlusion rates<sup>30,31</sup>. In our  
273 meta-analysis, only one study pertinent to the use of the HCCs was accepted for inclusion.  
274 Poncyłjusz *et al.*<sup>32</sup> performed a single-center controlled randomized trial to compare bare  
275 platinum coils (BPCs) and the HCCs, but reported no significant difference in occlusion  
276 effectiveness. The HCCs data from this study was not included in any of the meta-analyses  
277 due to the only data point for the ICA therapy with HCCs.

278 *Implications for the Development and Translation of Endovascular Devices*

279 Currently, most novel endovascular devices are compared with the GDCs in their pre-clinical  
280 and clinical trials. However, with the growth of flow diverting technology (both intra-saccular  
281 and extra-saccular), we questioned the *gold standard* status of the GDCs for unruptured  
282 aneurysms. Our results demonstrated that immediate occlusion of unruptured saccular ICAs is  
283 homogeneous across different coiling technologies, and that other endovascular devices do  
284 not offer an advantage over the use of the GDCs for unruptured saccular ICAs. However, the  
285 long-term complete occlusion of ICAs is more likely to occur after 18 months of treatment when  
286 the WEB devices are used. These findings could guide the clinical decisions on selecting an  
287 endovascular device that is better suited for the effectiveness evaluation of novel endovascular  
288 embolization system for unruptured ICA therapy.

### 289 Study Limitations

290 A meta-analysis is understood as the highest form of scientific evidence. However, most meta-  
291 analyses suffer from a high degree of heterogeneity between the studies used to perform  
292 them, in addition to very low availability of data that suffices I/E criteria in the literature. These  
293 factors played a significant role in our study. This heterogeneity can be induced by differences  
294 in study design, prospective or retrospective data generation and gathering, experience of  
295 neurosurgeons with the studied endovascular device, use of internal or centralized  
296 assessment of angiographic outcomes, among several other factors. In this study, we aimed at  
297 reducing the chances of Type II error by including study-specific variability in the assessment  
298 of our data. To do this, all our meta-analyzed metrics (averages and proportions) were  
299 calculated using random effects models, which have the great advantage of providing  
300 homogeneous weights for all studies in the analysis. In addition, the long-term modeling of  
301 RROC-I probability as a function of follow-up time in months was performed using a logistic  
302 GLMM, which also accounts for the random effects associated with study-specific variability.

303 Another important limitation in our analysis is related to a low availability of angiographic  
304 outcomes in the long-term follow-up (>2 years) of ICAs treated with endovascular devices. This  
305 is related to different factors: (i) the WEB became available for clinical use in Europe in 2011  
306 and later in other regions; long-term prospective trials have started to become available  
307 recently, but more data is expected to be published in the coming decade; (ii) flow diverters  
308 can be applied to more ICA geometries than other endovascular devices, including fusiform  
309 and dissecting aneurysms; in this study, we aimed at including unruptured saccular aneurysms  
310 only, which led to the rejection of a relatively high number of studies that reported angiographic

311 outcomes for all types of geometries together; (iii) we intended to perform analysis of the  
312 HCCs as individual endovascular devices; however, it is frequently applied as a “finishing” coil  
313 after occupying most of the aneurysm space with bare GDCs. The reporting of this type of  
314 procedure is inconsistent across literature, which led our protocol to be designed to only  
315 include studies where the HCCs were used as the only type of coil in the aneurysm; (iv) novel  
316 devices, including the Medina embolic device,<sup>33</sup> the CNS, the LUNA embolization system<sup>34</sup>,  
317 among other flow diverting devices are still “young” in the endovascular market, and their  
318 available data did not fulfill our I/E criteria.

### 319 Conclusions

320 Endovascular therapy for unruptured saccular ICAs has benefited from the emergence of novel  
321 technology in the last decade. Intra-saccular and extra-saccular flow diverters are some of the  
322 most notable technologies for the treatment of a wide array of ICA geometries, rupture status,  
323 and anatomic location. However, the GDCs, and the assisting technology used to improve its  
324 applicability, remains a great tool for endovascular embolization of unruptured saccular ICAs.  
325 The immediate RROC rates for the GDCs are yet to be improved and future developments in  
326 endovascular ICA therapeutics should aim to address this long-standing limitation to reduce  
327 aneurysm recurrence. Nevertheless, the WEB device shows great promise in reducing periods  
328 for progressive complete occlusion, as demonstrated in this meta-analysis.

### 329 **AVAILABILITY OF DATA**

330 Data not included in the Supplemental Data will be available upon request to the authors,  
331 including templates for data collection, a list of rejected studies after screening, raw extracted  
332 data from the included studies and scripts from R Studio for data analysis.

### 333 **AUTHOR CONTRIBUTION**

334 S.A.P.-C. contributed to conceptualization, study design, screening of studies at all stages of  
335 the systematic search, data extraction, statistical design, and analysis, and writing the original  
336 draft. E.R.J contributed as a reviewer in the screening of studies for the systematic search and  
337 data extraction. K.A.L, L.R.T. and T.L.C. assisted in the screening of studies for the systematic  
338 search. Y.D.Z. contributed to study design and statistical analysis. B.N.B. contributed to  
339 conceptualization and manuscript editing. C.-H.L. contributed to conceptualization,  
340 supervision, manuscript editing, and funding acquisition. All authors read and approved the  
341 final article.

342 **FUNDING INFORMATION**

343 We acknowledge funding support from the National Institutes of Health (NIH) Grant R01  
344 HL159475, OCAST Health Research Program (HR-18-002), and the OSCTR Pilot Grant  
345 Program. S.A.P.-C was supported in part by the University of Oklahoma Graduate College  
346 Alumni Fellowship.

347 **DISCLOSURE STATEMENT**

348 The authors declare no competing financial interests.

349 **REFERENCES**

- 350 1. Guglielmi, G., Viñuela, F., Dion, J., *et al.* Electrothrombosis of saccular aneurysms via  
351 endovascular approach: Part 2: Preliminary clinical experience. *Journal of Neurosurgery*  
352 **75**, 8, 1991. doi: 10.3171/jns.1991.75.1.0008
- 353 2. Guglielmi, G., Vinuela, F., Sepetka, I., *et al.* Electrothrombosis of saccular aneurysms via  
354 endovascular approach. Part 1: Electrochemical basis, technique, and experimental  
355 results. *Journal of Neurosurgery* **75**, 1, 1991. doi: 10.3171/jns.1991.75.1.0001
- 356 3. Claiborne, J.S., Wilson, C.B., Halbach, V.V., *et al.* Endovascular and surgical treatment of  
357 unruptured cerebral aneurysms: Comparison of risks. *Annals of Neurology* **48**, 11, 2000.  
358 doi: 10.1002/1531-8249(200007)48:1<11::aid-ana4>3.3.co;2-m
- 359 4. Molyneux, A.J., Kerr, R.S., Yu, L.-M., *et al.* International subarachnoid aneurysm trial (isat)  
360 of neurosurgical clipping versus endovascular coiling in 2143 patients with ruptured  
361 intracranial aneurysms: A randomised comparison of effects on survival, dependency,  
362 seizures, rebleeding, subgroups, and aneurysm occlusion. *Lancet* **366**, 809, 2005. doi:  
363 10.1053/jscd.2002.130390
- 364 5. Kang, X.K., Guo, S.F., Lei, Y., *et al.* Endovascular coiling versus surgical clipping for the  
365 treatment of unruptured cerebral aneurysms: Direct comparison of procedure-related  
366 complications. *Medicine (Baltimore)* **99**, e19654, 2020. doi:  
367 10.1097/md.00000000000019654
- 368 6. Chai, C.L., Jeon, J.P., Tsai, Y.-H., *et al.* Endovascular intervention versus surgery in  
369 ruptured intracranial aneurysms in equipoise. *Stroke* **51**, 1703, 2020. doi:  
370 doi:10.1161/STROKEAHA.120.028798
- 371 7. Laurent, D., Lucke-Wold, B., Leary, O., *et al.* The evolution of endovascular therapy for  
372 intracranial aneurysms: Historical perspective and next frontiers. *Neuroscience Insights*  
373 **17**, 26331055221117560, 2022. doi: 10.1177/26331055221117560
- 374 8. White, P.M., Lewis, S.C., Gholkar, A., *et al.* Hydrogel-coated coils versus bare platinum  
375 coils for the endovascular treatment of intracranial aneurysms (HELPS): A randomised  
376 controlled trial. *Lancet* **377**, 1655, 2011. doi: 10.1016/S0140-6736(11)60408-X
- 377 9. Alain, B., Marta Aguilar, P., Hans, H., *et al.* Diversion-p64: Results from an international,  
378 prospective, multicenter, single-arm post-market study to assess the safety and



- 379 effectiveness of the p64 flow modulation device. *Journal of NeuroInterventional Surgery*  
380 **14**, 898, 2022. doi: 10.1136/neurintsurg-2021-017809
- 381 10. Tibor, B., David, F.K., Isil, S., *et al.* Pipeline for uncoilable or failed aneurysms: Results  
382 from a multicenter clinical trial. *Radiology*, 2013. doi: 10.1148/radiol.13120099
- 383 11. Piano, M., Valvassori, L., Lozupone, E., *et al.* Fred Italian registry: A multicenter  
384 experience with the flow re-direction endoluminal device for intracranial aneurysms.  
385 *Journal of Neurosurgery*, 1, 2019. doi: 10.3171/2019.1.JNS183005
- 386 12. Issa, R., Al-Homedi, Z., Syed, D.H., *et al.* Surpass evolve flow diverter for the treatment of  
387 intracranial aneurysm: A systematic review. *Brain Sciences* **12**, 810, 2022. doi:  
388 10.3390/brainsci12060810
- 389 13. van Rooij, S., Sprengers, M., Peluso, J., *et al.* A systematic review and meta-analysis of  
390 woven endobridge single layer for treatment of intracranial aneurysms. *Interventional*  
391 *Neuroradiology* **26**, 455, 2020. doi: 10.1177/1591019920904421
- 392 14. Biondi, A., Primikiris, P., Vitale, G., *et al.* Endosaccular flow disruption with the contour  
393 neurovascular system: Angiographic and clinical results in a single-center study of 60  
394 unruptured intracranial aneurysms. *Journal of NeuroInterventional Surgery*, 2022. doi:  
395 10.1136/jnis-2022-019271
- 396 15. Pineda-Castillo, S.A., Stiles, A.M., Bohnstedt, B.N., *et al.* Shape memory polymer-based  
397 endovascular devices: Design criteria and future perspective. *Polymers* **14**, 2526, 2022.  
398 doi: 10.3390/polym14132526
- 399 16. Sadato, A., Hayakawa, M., Adachi, K., *et al.* Large residual volume, not low packing  
400 density, is the most influential risk factor for recanalization after coil embolization of  
401 cerebral aneurysms. *PLoS ONE* **11**, e0155062, 2016. doi: 10.1371/journal.pone.0155062
- 402 17. Tawfik, G.M., Dila, K.A.S., Mohamed, M.Y.F., *et al.* A step by step guide for conducting a  
403 systematic review and meta-analysis with simulation data. *Tropical Medicine and Health*  
404 **47**, 46, 2019. doi: 10.1186/s41182-019-0165-6
- 405 18. Moher, D., Liberati, A., Tetzlaff, J., *et al.* Preferred reporting items for systematic reviews  
406 and meta-analyses: The PRISMA statement. *Journal of Clinical Epidemiology* **62**, 1006,  
407 2009. doi: 10.1016/j.jclinepi.2009.06.005

- 408 19. McKenzie, J.E., Brennan, S.E., Ryan, R.E., *et al.* Defining the criteria for including studies  
409 and how they will be grouped for the synthesis. *Cochrane Handbook for Systematic*  
410 *Reviews of Interventions* 2019. pp. 33. doi: 10.1002/9781119536604.ch3
- 411 20. Balduzzi, S., Rücker, G., and Schwarzer, G. How to perform a meta-analysis with R: A  
412 practical tutorial. *Evidence Based Mental Health* **22**, 153, 2019. doi: 10.1136/ebmental-  
413 2019-300117
- 414 21. Murayama, Y., Nien, Y.L., Duckwiler, G., *et al.* Guglielmi detachable coil embolization of  
415 cerebral aneurysms: 11 years' experience. *Journal of Neurosurgery* **98**, 959, 2003. doi:  
416 10.3171/jns.2003.98.5.0959
- 417 22. Lee, K.S., Zhang, J.J.Y., Nguyen, V., *et al.* The evolution of intracranial aneurysm  
418 treatment techniques and future directions. *Neurosurgical Review* **45**, 1, 2022. doi:  
419 10.1007/s10143-021-01543-z
- 420 23. Ravindran, K., Salem, M.M., Alturki, A.Y., *et al.* Endothelialization following flow diversion  
421 for intracranial aneurysms: A systematic review. *American Journal of Neuroradiology* **40**,  
422 295, 2019. doi: 10.3174/ajnr.A5955
- 423 24. Grunwald, I.Q., Papanagiotou, P., Struffert, T., *et al.* Recanalization after endovascular  
424 treatment of intracerebral aneurysms. *Neuroradiology* **49**, 41, 2007. doi: 10.1007/s00234-  
425 006-0153-5
- 426 25. Vivanco-Suarez, J., Wallace, A.N., Dandapat, S., *et al.* Stent-assisted coiling versus  
427 balloon-assisted coiling for the treatment of ruptured wide-necked aneurysms: A 2-center  
428 experience. *Stroke: Vascular and Interventional Neurology* **3**, e000456, 2023. doi:  
429 doi:10.1161/SVIN.122.000456
- 430 26. Waldeck, S., Chapot, R., von Falck, C., *et al.* A comparative evaluation of standard and  
431 balloon-assisted coiling of intracranial aneurysms based on neurophysiological monitoring.  
432 *Journal of Clinical Medicine* **11**, 677, 2022. doi: 10.3390/jcm11030677
- 433 27. Chalouhi, N., Starke, R.M., Koltz, M.T., *et al.* Stent-assisted coiling versus balloon  
434 remodeling of wide-neck aneurysms: Comparison of angiographic outcomes. *American*  
435 *Journal of Neuroradiology* **34**, 1987, 2013. doi: 10.3174/ajnr.A3538
- 436 28. Asnafi, S., Rouchaud, A., Pierot, L., *et al.* Efficacy and safety of the woven endobridge  
437 (WEB) device for the treatment of intracranial aneurysms: A systematic review and meta-  
438 analysis. *American Journal of Neuroradiology* **37**, 2287, 2016. doi: 10.3174/ajnr.A4900

- 439 29. Akhunbay-Fudge, C.Y., Deniz, K., Tyagi, A.K., *et al.* Endovascular treatment of wide-  
440 necked intracranial aneurysms using the novel contour neurovascular system: A single-  
441 center safety and feasibility study. *Journal of NeuroInterventional Surgery* **12**, 987, 2020.  
442 doi: 10.1136/neurintsurg-2019-015628
- 443 30. Xue, T., Chen, Z., Lin, W., *et al.* Hydrogel coils versus bare platinum coils for the  
444 endovascular treatment of intracranial aneurysms: A meta-analysis of randomized  
445 controlled trials. *BMC Neurology* **18**, 2018. doi: 10.1186/s12883-018-1171-8
- 446 31. Taschner, C.A., Chapot, R., Costalat, V., *et al.* Second-generation hydrogel coils for the  
447 endovascular treatment of intracranial aneurysms: A randomized controlled trial. *Stroke*  
448 **49**, 667, 2018. doi: 10.1161/STROKEAHA.117.018707
- 449 32. Poncyłjusz, W., Zarzycki, A., Zwarzany, Ł., *et al.* Bare platinum coils vs. Hydrocoil in the  
450 treatment of unruptured intracranial aneurysms: A single center randomized controlled  
451 study. *European Journal of Radiology* **84**, 261, 2015. doi: 10.1016/j.ejrad.2014.11.002
- 452 33. Aguilar Perez, M., Bhogal, P., Martinez Moreno, R., *et al.* The medina embolic device:  
453 Early clinical experience from a single center. *Journal of Neurointerventional Surgery* **9**,  
454 77, 2017. doi: 10.1136/neurintsurg-2016-012539
- 455 34. Pötin, M., Biondi, A., Sourour, N., *et al.* The luna aneurysm embolization system for  
456 intracranial aneurysm treatment: Short-term, mid-term and long-term clinical and  
457 angiographic results. *Journal of Neurointerventional Surgery* **10**, e34, 2018. doi:  
458 10.1136/neurintsurg-2018-013767